ISCO (International Stem Cell) ROE %: 0.00% (As of Mar. 2026)


ISCO International Stem Cell Corp ISCO
24 GF Score
Price $0.18
GF Value $0.13
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is International Stem Cell ROE %?

International Stem Cell ISCO -10.50% 24 ROE % is 0.00% as of Mar. 2026. GuruFocus rates ISCO with a GF Score™ of 24/100 and a GF Value™ of $0.13 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,248 Biotechnology companies, International Stem Cell ranks worse than 80128.13% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. International Stem Cell's annualized net income for the quarter that ended in Mar. 2026 was $-0.88 Mil. International Stem Cell's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $-4.14 Mil. Therefore, International Stem Cell's annualized ROE % for the quarter that ended in Mar. 2026 was N/A%.

The historical rank and industry rank for International Stem Cell's ROE % or its related term are showing as below:

ISCO's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -38.26
* Ranked among companies with meaningful ROE % only.

International Stem Cell  (OTCPK:ISCO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-0.88/-4.138
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.88 / 9.26)*(9.26 / 4.976)*(4.976 / -4.138)
=Net Margin %*Asset Turnover*Equity Multiplier
=-9.5 %*1.8609*N/A
=ROA %*Equity Multiplier
=-17.68 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-0.88/-4.138
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-0.88 / -0.88) * (-0.88 / -0.76) * (-0.76 / 9.26) * (9.26 / 4.976) * (4.976 / -4.138)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.1579 * -8.21 % * 1.8609 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


International Stem Cell ROE % Related Terms


International Stem Cell ROE % Historical Data

* Premium members only.

The historical data trend for International Stem Cell's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

International Stem Cell ROE % Chart

International Stem Cell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

International Stem Cell Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 Negative Equity Negative Equity 0.00 0.00

ISCO vs ZVSA, AXIM, HEPA: ROE % Comparison

For the Biotechnology subindustry, International Stem Cell's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


International Stem Cell ROE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, International Stem Cell's ROE % distribution charts can be found below:

* The bar in red indicates where International Stem Cell's ROE % falls into.


ISCO
24GF Score
International Stem Cell Corp ISCO
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

International Stem Cell ROE % Calculation

International Stem Cell's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=-0.418/( (-3.93+-4.06)/ 2 )
=-0.418/-3.995
=N/A %

International Stem Cell's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Dec. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=-0.88/( (-4.06+-4.216)/ 2 )
=-0.88/-4.138
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
International Stem Cell (ISCO) has a ROE % of 0.00% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on International Stem Cell and its competitors. According to the industry distribution chart, International Stem Cell ranks #999999 out of 1248 companies in the Biotechnology industry.
Is International Stem Cell's ROE % too high?
International Stem Cell's current ROE % is 0.00%. Based on the distribution chart, International Stem Cell ranks #999999 out of 1248 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, International Stem Cell has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does International Stem Cell's ROE % compare to ZVSA and AXIM?
According to the Biotechnology industry distribution chart, International Stem Cell ranks #999999 out of 1248 companies for ROE %. This places International Stem Cell in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on International Stem Cell and its competitors. International Stem Cell's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Stem Cell stock overvalued right now?
Based on GuruFocus' analysis, International Stem Cell (ISCO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.18 — trading 37.7% above its estimated fair value. The current ROE % is 0.00%. International Stem Cell's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For International Stem Cell (ISCO), the current ROE % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is International Stem Cell (ISCO) Overvalued in 2026?

Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued. The current stock price of $0.18 is trading 37.7% above its estimated GF Value™ of $0.13. GuruFocus considers International Stem Cell to be Significantly Overvalued.

Key valuation signals for ISCO:

  • ROE %: 0.00%
  • GF Value™: $0.13 vs. price of $0.18 (37.7% above fair value)
  • GF Score™: 24/100 with 6 warning signs

No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


International Stem Cell Business Description

Address 9745 Businesspark Avenue, San Diego, CA, USA, 92131
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
24GF Score

Get the complete analysis for ISCO

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.18
Price
$0.13
GF Value